Publications by authors named "D J DeAngelo"
Article Synopsis
- - In the last decade, significant advancements have been made in treating adults with newly diagnosed B-cell acute lymphoblastic leukaemia, driven by better understanding of the disease and innovative treatment strategies like incorporating immunotherapy and tyrosine kinase inhibitors.
- - Despite these advancements, adults still have worse outcomes compared to children, facing higher rates of treatment failure and complications, leading to ongoing use of transplant consolidation for high-risk cases.
- - The article emphasizes the need for new trial designs to further improve treatment strategies and personalize care for adults with acute lymphoblastic leukaemia, sharing insights from practices across Europe and other continents.
Background: Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve persistence.
Methods: We conducted a phase 1b-2 multicenter study of obe-cel in adults (≥18 years of age) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The main cohort, cohort 2A, included patients with morphologic disease; patients in cohort 2B had measurable residual disease.
Article Synopsis
- In a phase 1b study, the BCL2 inhibitor venetoclax was tested alongside a reduced chemotherapy regimen in patients with acute lymphoblastic leukemia (ALL) to determine the optimal dose while minimizing toxicity.
- The study included 19 patients, with 90.9% of those newly diagnosed achieving complete remission and showing no deaths or serious toxicities within 60 days.
- Results indicated that the combination therapy is well-tolerated and effective, especially in newly diagnosed patients, with a median disease-free survival of 54.6 months.
Article Synopsis
- - Asparaginase-containing regimens for acute lymphoblastic leukemia (ALL) result in a significant prevalence of venous thromboembolism (VTE) among adolescents and young adults, with 1-year and 2-year cumulative incidences of 31.9% and 33.5%, respectively, particularly during the ASP-based consolidation phase.
- - The study revealed that overweight or obese patients had a higher risk of developing VTE (39.2%) compared to those with a normal BMI (29.0%), and overall survival rates were similar regardless of VTE occurrence, at around 91.5%.
- - Despite the frequent occurrence of VTE, especially types like pulmonary embolism and deep vein thrombosis,
Article Synopsis
- - The NCCN Guidelines for acute lymphoblastic leukemia (ALL) offer management recommendations that prioritize classifying ALL subtypes using immunophenotype and cytogenetic/molecular markers.
- - The guidelines emphasize risk assessment and stratification to tailor therapy for both Ph-positive and Ph-negative ALL, specifically addressing treatment for adolescent, young adult, and adult patients.
- - This excerpt highlights treatment recommendations specifically for adults newly diagnosed with Ph-negative ALL, grounded in the latest evidence-based research.